Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC)

Q: What does CUSIP 761330109 represent in this 13F holders report?

CUSIP 761330109 is the security identifier for RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share used to aggregate holder disclosures.

Q: How many institutions held RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share in Q1 2024?

182 institutional investors reported RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share for Q1 2024. Use the holders table for investor-level position and value details.

CUSIP: 761330109

Q1 2024 13F Holders as of 31 Mar 2024

Type / Class: Equity / Common Stock, par value $0.001 per share
Shares outstanding: 104,661,494
Total 13F shares: 83,208,743
Share change: +10,713,240
Total reported value: $409,387,692
Put/Call ratio: 65%
Price per share: $4.92
Number of holders: 182
Value change: +$36,028,524
Number of buys: 98
Number of sells: 90

Quarterly Holders Quick Answers

What is CUSIP 761330109?
CUSIP 761330109 identifies RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q2 2024
Previous quarter: Q4 2023

Recent filing periods for CUSIP 761330109:

Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024

Top shareholders of RVNC - Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Capital World Investors	13F	Company	11%	11,939,076	$104,944,478	—	31 Dec 2023	13F
BlackRock Finance, Inc.	13F	Company	7.1%	7,453,371	$65,515,131	—	31 Dec 2023	13F
Palo Alto Investors LP	13F	Company	5%	5,237,284	$46,035,726	—	31 Dec 2023	13F
VANGUARD GROUP INC	13F	Company	4.8%	5,069,625	$44,562,004	—	31 Dec 2023	13F
FRANKLIN RESOURCES INC	13F	Company	4.5%	4,749,539	$41,748,450	—	31 Dec 2023	13F
JPMORGAN CHASE & CO	13F	Company	4.4%	4,643,419	$40,815,652	—	31 Dec 2023	13F
Polar Capital Holdings Plc	13F	Company	3%	3,169,239	$27,857,611	—	31 Dec 2023	13F
STATE STREET CORP	13F	Company	2.4%	2,521,693	$22,165,681	—	31 Dec 2023	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	1.8%	1,924,421	$16,917,609	—	31 Dec 2023	13F
Invesco Ltd.	13F	Company	1.5%	1,602,622	$14,087,047	—	31 Dec 2023	13F
Rubric Capital Management LP	13F	Company	1.4%	1,461,474	$12,846,356	—	31 Dec 2023	13F
CIBC Asset Management Inc	13F	Company	1.1%	1,147,294	$10,084,714	—	31 Dec 2023	13F
JENNISON ASSOCIATES LLC	13F	Company	0.99%	1,032,352	$9,074,374	—	31 Dec 2023	13F
BAMCO INC /NY/	13F	Company	0.98%	1,023,663	$8,997,998	—	31 Dec 2023	13F
Walleye Capital LLC	13F	Company	0.89%	927,814	$8,155,485	—	31 Dec 2023	13F
NORTHERN TRUST CORP	13F	Company	0.85%	887,536	$7,801,441	—	31 Dec 2023	13F
MORGAN STANLEY	13F	Company	0.84%	879,249	$7,728,599	—	31 Dec 2023	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.75%	783,628	$6,888,090	—	31 Dec 2023	13F
RICE HALL JAMES & ASSOCIATES, LLC	13F	Company	0.72%	758,048	$6,663,242	—	31 Dec 2023	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.65%	677,364	$5,954,030	—	31 Dec 2023	13F
EULAV Asset Management	13F	Company	0.6%	630,000	$5,537,700	—	31 Dec 2023	13F
Nuveen Asset Management, LLC	13F	Company	0.51%	533,196	$4,686,793	—	31 Dec 2023	13F
Qube Research & Technologies Ltd	13F	Company	0.48%	503,874	$4,429,053	—	31 Dec 2023	13F
Aubrey Rankin	3/4/5	Director	— class O/S missing	570,004	$4,257,930	—	15 Mar 2022	3/4/5
Rhenman & Partners Asset Management AB	13F	Company	0.45%	475,872	$4,182,915	—	31 Dec 2023	13F
Essex Woodlands Management, Inc.	13F	Company	0.44%	457,085	$4,017,777	—	31 Dec 2023	13F
Integral Health Asset Management, LLC	13F	Company	0.43%	450,000	$3,955,500	—	31 Dec 2023	13F
WELLINGTON MANAGEMENT GROUP LLP	13F	Company	0.43%	449,685	$3,952,731	—	31 Dec 2023	13F
D. E. Shaw & Co., Inc.	13F	Company	0.39%	411,750	$3,619,282	—	31 Dec 2023	13F
HighTower Advisors, LLC	13F	Company	0.39%	406,421	$3,573,000	—	31 Dec 2023	13F
Ghost Tree Capital, LLC	13F	Company	0.36%	375,000	$3,296,250	—	31 Dec 2023	13F
BALYASNY ASSET MANAGEMENT L.P.	13F	Company	0.35%	362,760	$3,188,660	—	31 Dec 2023	13F
BARCLAYS PLC	13F	Company	0.34%	357,556	$3,142,917	—	31 Dec 2023	13F
CITADEL ADVISORS LLC	13F	Company	0.34%	353,662	$3,108,689	—	31 Dec 2023	13F
Bank of New York Mellon Corp	13F	Company	0.32%	335,185	$2,946,277	—	31 Dec 2023	13F
Cubist Systematic Strategies, LLC	13F	Company	0.29%	305,447	$2,684,878	—	31 Dec 2023	13F
BLAIR WILLIAM & CO/IL	13F	Company	0.28%	292,949	$2,575,022	—	31 Dec 2023	13F
SCHRODER INVESTMENT MANAGEMENT GROUP	13F	Company	0.28%	288,726	$2,537,902	—	31 Dec 2023	13F
VOLORIDGE INVESTMENT MANAGEMENT, LLC	13F	Company	0.26%	271,852	$2,389,579	—	31 Dec 2023	13F
PRINCIPAL FINANCIAL GROUP INC	13F	Company	0.26%	269,718	$2,370,821	—	31 Dec 2023	13F
Schonfeld Strategic Advisors LLC	13F	Company	0.25%	266,039	$2,338,481	—	31 Dec 2023	13F
DCF Advisers, LLC	13F	Company	0.25%	256,872	$2,257,905	—	31 Dec 2023	13F
GREAT LAKES ADVISORS, LLC	13F	Company	0.22%	233,958	$2,056,491	—	31 Dec 2023	13F
AlphaCentric Advisors LLC	13F	Company	0.21%	220,000	$1,933,800	—	31 Dec 2023	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.2%	208,673	$1,834,235	—	31 Dec 2023	13F
Susquehanna Portfolio Strategies, LLC	13F	Company	0.19%	203,192	$1,786,058	—	31 Dec 2023	13F
Assenagon Asset Management S.A.	13F	Company	0.19%	198,846	$1,747,856	—	31 Dec 2023	13F
UBS Group AG	13F	Company	0.19%	194,153	$1,706,605	—	31 Dec 2023	13F
AMERIPRISE FINANCIAL INC	13F	Company	0.17%	178,103	$1,565,525	—	31 Dec 2023	13F
CREDIT SUISSE AG/	13F	Company	0.16%	172,007	$1,511,941	—	31 Dec 2023	13F

Institutional Holders of Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) as of Q1 2024

As of 31 Mar 2024, Revance Therapeutics, Inc. - Common Stock, par value $0.001 per share (RVNC) was held by 182 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 83,208,743 shares. The largest 10 holders included Capital World Investors, BlackRock Inc., FRANKLIN RESOURCES INC, VANGUARD GROUP INC, Palo Alto Investors LP, Polar Capital Holdings Plc, JPMORGAN CHASE & CO, BARCLAYS PLC, Rubric Capital Management LP, and STATE STREET CORP. This page lists 182 institutional shareholders reporting positions in this security for the Q1 2024 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q1 2024 vs Q4 2023 Across Filers

Q4 2023 holders

188

Q1 2024 holders

182

Holder diff

-6

Investor	Q4 2023 Shares	Q1 2024 Shares	Share Diff	Share Chg %	Q4 2023 Value $	Q1 2024 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.